Samenvatting
Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup of cancers (‘PD-Lomas’) is driving the clinical research strategies for the next generation of combination immunotherapy.
Originele taal-2 | Engels |
---|---|
Pagina's (van-tot) | 3-5 |
Aantal pagina's | 3 |
Tijdschrift | British Journal of Cancer |
Volume | 120 |
Nummer van het tijdschrift | 1 |
DOI's | |
Status | Gepubliceerd - 8 jan. 2019 |
Extern gepubliceerd | Ja |